Clinical Trials | December 09, 2024
Metropolis Healthcare acquires Core Diagnostics for Rs. 246.8 Cr
Aims to become India’s leading cancer testing company
Aims to become India’s leading cancer testing company
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
For people with relapsed or refractory diffuse large B-cell lymphoma
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
With the addition of Karsanbhai, the Merck board will consist of 13 members
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Subscribe To Our Newsletter & Stay Updated
